A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study (AHELP) of Apatinib in Patients With Hepatocellular Carcinoma After Systemic TherapyChemotherapy and/or Targeted Therapy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Rivoceranib (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms AHELP
- Sponsors Jiangsu Hengrui Medicine Co.
- 04 Jul 2017 Planned number of patients changed from 360 to 400.
- 04 Jul 2017 Planned End Date changed from 1 Jun 2017 to 30 Jun 2018.
- 04 Jul 2017 Planned primary completion date changed from 1 Jan 2017 to 31 Dec 2017.